Peptide Receptor Radionuclide Therapy Performed Shortly After Administration of Long-Acting Octreotide.
Journal
Clinical nuclear medicine
ISSN: 1536-0229
Titre abrégé: Clin Nucl Med
Pays: United States
ID NLM: 7611109
Informations de publication
Date de publication:
01 Dec 2023
01 Dec 2023
Historique:
medline:
8
11
2023
pubmed:
17
10
2023
entrez:
16
10
2023
Statut:
ppublish
Résumé
We present a case of a 68-year-old man with metastatic small bowel neuroendocrine tumor who underwent 4 cycles of peptide receptor radionuclide therapy with 177 Lu-DOTATATE. For his first 3 cycles, therapy was performed approximately 4 weeks after his last dose of octreotide LAR. Because of miscommunication in scheduling, his fourth cycle was performed only 48 hours after his last full dose of octreotide LAR. Despite this, we found that the tumoral uptake was not reduced at all, which may add to the increasing evidence on the nonnecessity of stopping somatostatin analogs before peptide receptor radionuclide therapy.
Identifiants
pubmed: 37844418
doi: 10.1097/RLU.0000000000004906
pii: 00003072-990000000-00751
doi:
Substances chimiques
Octreotide
RWM8CCW8GP
Organometallic Compounds
0
Radioisotopes
0
Receptors, Peptide
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1086-1088Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of interest and sources of funding: none declared.
Références
Kwekkeboom DJ, Krenning EP, Lebtahi R, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. Neuroendocrinology . 2009;90:220–226.
Hope TA, Bodei L, Chan JA, et al. NANETS/SNMMI consensus statement on patient selection and appropriate use of (177)Lu-DOTATATE peptide receptor radionuclide therapy. J Nucl Med . 2020;61:222–227.
Buscombe JR. Evidence base for the use of PRRT. Semin Nucl Med . 2020;50:399–404.
Aalbersberg EA, de Wit-van der Veen BJ, Versleijen MWJ, et al. Influence of lanreotide on uptake of 68 Ga-DOTATATE in patients with neuroendocrine tumours: a prospective intra-patient evaluation. Eur J Nucl Med Mol Imaging . 2019;46:696–703.
Gålne A, Almquist H, Almquist M, et al. A prospective observational study to evaluate the effects of long-acting somatostatin analogs on (68)Ga-DOTATATE uptake in patients with neuroendocrine tumors. J Nucl Med . 2019;60:1717–1723.
Haug AR, Rominger A, Mustafa M, et al. Treatment with octreotide does not reduce tumor uptake of (68)Ga-DOTATATE as measured by PET/CT in patients with neuroendocrine tumors. J Nucl Med . 2011;52:1679–1683.
Morland D, Laures N, Triumbari EKA, et al. Impact of cold somatostatin analog administration on somatostatin receptor imaging: a systematic review. Clin Nucl Med . 2023;48:467–473.
Chahid Y, Hashimi K, van de Garde EMW, et al. The influence of long-acting somatostatin analogs on 68 Ga-DOTATATE uptake in patients with neuroendocrine tumors. Clin Nucl Med . 2023;48:757–762.
Veerman CHAM, Siebinga H, de Vries-Huizing DMV, et al. The effect of long-acting somatostatin analogues on the uptake of [ 177 Lu]Lu-HA-DOTATATE. Eur J Nucl Med Mol Imaging . 2023;50:1434–1441.